452 related articles for article (PubMed ID: 9892155)
1. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.
Brilla CG; Scheer C; Rupp H
J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122
[TBL] [Abstract][Full Text] [Related]
3. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
4. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats.
Wada T; Kanagawa R; Ishimura Y; Inada Y; Nishikawa K
J Hypertens; 1995 Jan; 13(1):113-22. PubMed ID: 7759841
[TBL] [Abstract][Full Text] [Related]
5. Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Fujita H; Takeda K; Miki S; Morimoto S; Kawa T; Uchida A; Itoh H; Nakata T; Sasaki S; Nakagawa M
Hypertens Res; 1997 Dec; 20(4):263-7. PubMed ID: 9453261
[TBL] [Abstract][Full Text] [Related]
6. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
7. Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
Hara K; Kobayashi N; Watanabe S; Tsubokou Y; Matsuoka H
Am J Hypertens; 2001 Apr; 14(4 Pt 1):321-30. PubMed ID: 11336177
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.
Peng H; Carretero OA; Alfie ME; Masura JA; Rhaleb NE
Hypertension; 2001 Mar; 37(3):974-80. PubMed ID: 11244026
[TBL] [Abstract][Full Text] [Related]
9. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Hypertension; 2003 Mar; 41(3):493-8. PubMed ID: 12623949
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Pollock DM; Derebail VK; Yamamoto T; Pollock JS
Gen Pharmacol; 2000 May; 34(5):337-42. PubMed ID: 11368889
[TBL] [Abstract][Full Text] [Related]
12. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
13. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.
O'Brien D; Chunduri P; Iyer A; Brown L
Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):296-301. PubMed ID: 20041879
[TBL] [Abstract][Full Text] [Related]
14. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
15. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Nishimura M; Ohtsuka K; Sakamoto M; Nanbu A; Takahashi H; Yoshimura M
J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage.
Nishikawa K
J Hum Hypertens; 1998 May; 12(5):301-9. PubMed ID: 9655651
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
Pollock DM; Morsing P
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S116-9. PubMed ID: 9892151
[TBL] [Abstract][Full Text] [Related]
18. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Obata J; Nakamura T; Kuroyanagi R; Yoshida Y; Guo DF; Inagami T
Kidney Int Suppl; 1997 Dec; 63():S229-31. PubMed ID: 9407467
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of angiotensin II receptor blockade (candesartan) with angiotensin-converting enzyme inhibitor (quinapril) in rats with dilated cardiomyopathy.
Watanabe K; Juan W; Narasimman G; Ma M; Inoue M; Saito Y; Wahed MI; Nakazawa M; Hasegawa G; Naito M; Tachikawa H; Tanabe N; Kodama M; Aizawa Y; Yamamoto T; Yamaguchi K; Takahashi T
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S93-7. PubMed ID: 12693379
[TBL] [Abstract][Full Text] [Related]
20. Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension.
Zeng ZH; Luo BH; Gao YJ; Su CJ; He CC; Yi JJ; Li N; Lee RM
Eur J Pharmacol; 2004 Oct; 503(1-3):129-33. PubMed ID: 15496307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
